All In Biotech

Free tool

FAERS Monitor: Iclusig

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 203469 or its brand name (Iclusig, Ponatinib Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

5,237

Serious

4,483

86% of reports

Hospitalization

1,673

Death reported

1,478

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death756
  • off label use350
  • rash272
  • headache268
  • fatigue260
  • pyrexia255
  • neoplasm progression197
  • drug ineffective195
  • hypertension195
  • nausea195
  • constipation192
  • platelet count decreased166
  • arthralgia164
  • abdominal pain160
  • chronic myeloid leukaemia150

Reports by year received

View as table
YearReports
2013595
2014637
2015357
2016611
2017416
2018305
2019337
2020408
2021331
2022250
2023275
2024305
2025260
2026150

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,922 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
chronic myeloid leukaemiaSignal150134.8114.919,156
neoplasm progressionSignal19722.919.94,084
platelet count decreasedSignal1666.35.4732
hypertensionSignal1953.73.2385
constipationSignal1923.53.1350
deathSignal7563.53.31,423
pyrexiaSignal2553.02.6335
abdominal painSignal1602.82.4180
rashSignal2722.52.2250
headache2681.71.582
off label use3501.61.583
arthralgia1641.61.435
fatigue2601.31.223
nausea1951.00.90
drug ineffective1950.60.557

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.